Table 1.
Baseline characteristics
|
Control group (2019)
(n = 72 819) |
Lockdown group (2020)
(n = 57 589) |
SMD | |
|---|---|---|---|
| Age (years)* | 56.49(23.08) | 57.34(23.01) | 0.037 |
| < 30 | 13 104 (18.0) | 9461 (16.4) | |
| 30–39 | 10 611 (14.6) | 8744 (15.2) | |
| 40–49 | 7203 (9.9) | 5658 (9.8) | |
| 50–59 | 8127 (11.2) | 6318 (11.0) | |
| 60–75 | 14 294 (19.6) | 11 178 (19.4) | |
| > 75 | 19 501 (26.8) | 16 230 (28.2) | |
| Women | 40 452 (55.5) | 32 466 (56.4) | 0.017 |
| Charlson Co-morbidity Index score* | 0.42 (0.87) | 0.44 (0.89) | 0.026 |
| 0 | 54 382 (74.7) | 42 275 (73.4) | |
| 1–2 | 15 578 (21.4) | 12 856 (22.3) | |
| >3 | 2880 (4.0) | 2458 (4.3) | |
| Myocardial infarction | 875 (1.2) | 676 (1.2) | 0.003 |
| Congestive heart failure | 3698 (5.1) | 3140 (5.5) | 0.017 |
| Peripheral vascular disease | 2046 (2.8) | 1738 (3.0) | 0.012 |
| Cerebrovascular disease | 1700 (2.3) | 1352 (2.3) | 0.001 |
| Dementia | 3027 (4.2) | 2393 (4.2) | <0.001 |
| Chronic pulmonary disease | 2413 (3.3) | 2228 (3.9) | 0.030 |
| Rheumatic disease | 350 (0.5) | 300 (0.5) | 0.006 |
| Peptic ulcer disease | 427 (0.6) | 317 (0.6) | 0.005 |
| Mild liver disease | 684 (0.9) | 608 (1.1) | 0.012 |
| Diabetes without chronic complication | 5172 (7.1) | 4276 (7.4) | 0.013 |
| Diabetes with chronic complication | 1399 (1.9) | 1009 (1.8) | 0.013 |
| Hemiplegia or paraplegia | 1281 (1.8) | 1014 (1.8) | <0.001 |
| Renal disease | 2518 (3.5) | 2119 (3.7) | 0.012 |
| Any malignancy, including lymphoma and leukaemia, except malignant neoplasm of skin | 3330 (4.6) | 2933 (5.1) | 0.024 |
| Moderate or severe liver disease | 156 (0.2) | 154 (0.3) | 0.011 |
| Metastatic solid tumour | 1321 (1.8) | 1119 (1.9) | 0.01 |
| AIDS/HIV | 81 (0.1) | 54 (0.1) | 0.005 |
| Obesity | 3588 (4.9) | 3026 (5.3) | 0.015 |
Values in parentheses are percentages unless indicated otherwise; *values are mean(s.d.). SMD, standardized mean difference; AIDS/HIV, acquired immune deficiency syndrome/human imuunodeficiency virus.